Stock Image
IMAGE

XBRANE BIOPHARMA

MARKET CAP - 531M SEK
MARKET CAP - 531M SEK

ABOUT US

Xbrane Biopharma AB is a biotechnology company which develops biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development. Xbrane’s headquarter is located in Solna, just outside of Stockholm, and the company has research and development facilities in Sweden and in Italy. Xbrane has been listed on Nasdaq First North since 3 February 2016 with the ticker XBRANE.

Q&A WITH MARTIN ÅMARK  

Right arrow

How many staff members are on the team currently & do you find it difficult to find quality local and international staff?

At Xbrane Group we are 32 employees and together with the board of the directors Xbrane possess comprehensive international experience from several of the major global pharmaceutical companies. By being an international company with office in both Sweden and Italy, we are able to use our extensive international network in order to find highly qualified expertise.

Right arrow

Do any of the staff and or management team hold any shares within the company?

Yes, the majority of the management and staff have shares within the company.

Right arrow

During your time at the company, what's been your greatest achievement thus far?

It was when we signed the cooperation agreement with STADA last year. The cooperation made it possible for us to advance our development of Xlucane and to continue our journey towards being a world leading biosimilar developer.

Right arrow

What is your medium to long-term goal & has it been consistent for some time?

Our focus is on launching Xlucane to the market at patent expiry in 2022, which has been our goal since early on and has been consistent for some time. For the long term goals we are striving to be the world’s leading biosimilar developer.

Right arrow

What sets your company apart from others within your industry?

It would be our patented technology platform, performing significant higher yields in protein production compared to other standard technologies. Our internal competence within both the E. coli and CHO cells, which will lead us to our long term goal of becoming the world´s leading biosimilar company. As well as our well reputed collaboration partners and investors that has been of great support during our journey and will continue to be going forward.

Right arrow

Could you please share with us your favourite memory and or event since you joined the company?

It must be when we signed the cooperation agreement with STADA, it sure was a really proud moment in Xbranes history.

PRODUCTS & SERVICES

Product Image
Product Image
Product Image

MEDIA